Rchr
J-GLOBAL ID:201801016642010583   Update date: Jan. 17, 2024

Aoki Hironori

アオキ ヒロノリ | Aoki Hironori
Affiliation and department:
Research field  (2): Tumor diagnostics and therapeutics ,  Gastroenterology
Research keywords  (4): 大腸がん ,  分子生物学 ,  消化器病 ,  消化器内視鏡
Research theme for competitive and other funds  (4):
  • 2017 - 2019 新規大腸がん関連遺伝子と腸内細菌叢の解析による多発大腸がん発生機構の解明
  • 2016 - 2017 大腸低分化腺癌の分子機構解明と新規診断治療戦略の構築
  • 2015 - 2017 統合的ゲノム・エピゲノム解析による大腸低分化腺癌の分子病態と診断・治療法の開発
  • 2014 - 2014 CLINICAL PATHOLOGY AND MOLECULAR BIOLOGY FOR MIXED SERRATED LESIONS DIAGNOSED IN MAGNIFYING ENDOSCOPY.
Papers (17):
more...
MISC (18):
Lectures and oral presentations  (28):
  • Epigenetic silencing of SMOC1 is associated with development of colorectal traditional serrated adenomas
    (UEG Week 2017 2017)
  • Endoscopic and molecular characteristics in colorectal serrated lesions represent subclasses of the serrated neoplasia pathway
    (UEG Week 2017 2017)
  • 低分化成分を有する大腸SM(T1)癌のリスク因子の検討
    (日本消化器病学会雑誌 2017)
  • SMOC1のエピジェネティックなサイレンシングは大腸鋸歯状腺腫の発育進展に関連する
    (日本癌学会総会記事 2017)
  • 大腸鋸歯状腺腫においてDNAメチル化異常を示す遺伝子の同定と大腸癌への進展マーカーとしての可能性
    (日本大腸肛門病学会雑誌 2017)
more...
Awards (4):
  • 2017/11 - UEG Week 2017 Travel grant award Endoscopic and molecular characteristics in colorectal serrated lesions represent subclasses of the serrated neoplasia pathway
  • 2017/10 - 第25回日本消化器関連学会週間( JDDW 2017) ポスター優秀演題賞 低分化成分を有する大腸T1(SM)癌のリスク因子の検討
  • 2016/10 - UEG Week 2016 Travel grant award Subclasses of Type-II pit pattern reveal alternative tumorigenic pathways of colorectal serrated lesions
  • 2014/10 - UEG Week 2014 Oral Free Paper Prize Clinical pathology and molecular biology for mixed serrated lesions diagnosed in magnifying endoscopy.
Association Membership(s) (5):
日本消化管学会 ,  THE JAPANESE CANCER ASSOCIATION ,  THE JAPANESE SOCIETY OF INTERNAL MEDICINE ,  JAPANESE SOCIETY OF GASTROENTEROLOGY ,  JAPAN GASTROENTEROLOGICAL ENDOSCOPY SOCIETY
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page